Eli Lilly and Company

The Procter Gamble Company

Edward David Mihelich

Tulio Suarez

Gary A Hite

Michael LeRoy Phillips

Jason Scott Sawyer

Daniel Jon Sall

John Michael Morin, Jr

Michael Dean Kinnick

Nicholas J Bach

Robert D Dillard

Susan Elizabeth Draheim

Douglas Wade Beight

Alan M Warshawsky

Ho-Shen Lin

Michael Enrico Richett

Jolie Anne Bastian

Richard Waltz Harper

Benjamin Alan Anderson

Robert Theodore Vasileff

Michael Lyle Denney

Nancy Kay Harn

Richard Walter Schevitz

John Mcneill McGill, Iii

David W Snyder

Richard James Loncharich

Rosanne Bonjouklian

Peter J Doman

Stuart E Willetts

Christopher J Meade

A novel class of tricyclic compounds of the following formula (I) is disclosed together with the use of such compounds for inhibiting sPLAmediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

[object Object]

A novel class of tricyclic compounds of the following formula (I): (formula I); is disclosed together with the use of such compounds for inhibiting sPLAmediated release of fatty acids for treatment of inflammatory diseases such as septic shock 

Cyclohept[b]indole derivatives

A class of novel acylsulfonamide substituted indole compounds is disclosed together with the use of such compounds for inhibiting sPLAmediated release of fatty acids for treatment of inflammatory diseases such as septic shock.

Indole sPLA2 inhibitors

A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA mediated release of fatty acids for treatment of conditions such as septic shock.

Substituted tricyclics

A class of novel acylsulfonamide substituted indole compounds is disclosed together with the use of such compounds for inhibiting sPLA mediated release of fatty acids for treatment of inflammatory diseases.

A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA mediated release of fatty acids for treatment of inflammatory diseases such as septic shock.

A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA,mediated release of fatty acids for treatment of conditions such as septic shock.

A class of novel pyrazoles is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.

Pyrazoles as human non-pancreatic secretory phospholipase A.sub.2

This invention relates to N-hydroxy-N-[3-[2-(4'-halophenylthio)phenyl]prop-2-enyl]ureas, formulations containing those compounds and methods of using such compounds as 5-lipoxygenase inhibiting agents.

N-hydroxy-N-[3-[2-(halophenylthio)phenyl]prop-2-enyl]ureas as

This invention relates to N-hydroxy-N-[3-(2-substituted phenyl)prop-2-enyl]ureas and thioureas, formulations containing those compounds, and methods of using such compounds as 5-lipoxygenase inhibiting agents.

N-hydroxy-N-(3-(2-substituted phenyl)prop-2-enyl)ureas and thioureas

This invention relates to 2-(substituted)-N-hydroxy-N-alkylcinnamamides of the formula: ##STR1## where R.sup.1 is C.sub.1 -C.sub.4 alkyl;

5-Lipoxygenase inhibitors

This invention provides certain furanone derivatives, their pharmaceutical formulations, and their use in a method for treating inflammation, asthma, or allergies.

Furanone derivatives

A novel process for the oxidation of olefins to the corresponding alpha-epoxy alcohols which can be incorporated in the total synthesis of members of a novel class of prostaglandin analogues. Olefins are reacted with singlet oxygen in the presence of a group IVB, VB or VIB transition metal catalysts, excluding chromium. The reaction is fast and highly selective to the alpha-epoxy alcohol. When cyclopentene is oxidized in the process of the invention, high yields of cis 2,3-epoxy cyclopentan-1-01-are obtained. The latter compound is used as a starting material in the synthesis of prostaglandin analogues. The prostanoids of the invention are characterized by an oxa group replacing the methylene group at the 7-position, and the absence of a hydroxyl or other substituent at the 11-position. Members of this class of prostanoids show important cytoprotective properties in animal tests.

Novel prostaglandin analogues and process for making same

A novel process for the oxidation of olefins to the corresponding alpha-epoxy alcohols which can be incorporated in the total synthesis of members of a novel class of prostaglandin analogues. Olefins are reacted with singlet oxygen in the presence of a group IVB, VB or VIB transition metal catalyst, excluding chromium. The reaction is fast and highly selective to the alpha-epoxy alcohol. When cyclopentene is oxidized in the process of the invention, high yields of cis 2,3-epoxy-cyclopentan-1-ol are obtained. The latter compound is used as a starting material in the synthesis of prostaglandin analogues. The prostanoids of the invention are characterized by an oxa group replacing the methylene group at the 7-position, and the absence of a hydroxyl or other substituent at the 11-position. Members of this class of prostanoids show important cytoprotective properties in animal tests.

Growing community of inventors

Carmel, IN, United States of America

Edward David Mihelich